Stents for Post-Thrombotic Syndrome: How They Relieve Symptoms

A landmark clinical trial has demonstrated that a minimally invasive procedure using stents can significantly ease symptoms for patients suffering from post-thrombotic syndrome (PTS), a debilitating complication of deep vein thrombosis (DVT). The findings, published in The New England Journal of Medicine, offer new hope for a condition that has long lacked proven treatment options.

What Is Post-Thrombotic Syndrome?

Post-thrombotic syndrome develops in up to half of patients after a deep vein thrombosis, a blood clot that forms in a deep vein, most commonly in the leg. The condition occurs when damage from the clot leaves veins narrowed, blocked, or inflamed, disrupting normal blood flow. Over time, this can lead to chronic leg pain, swelling, skin changes, and even ulcers, severely limiting mobility and quality of life.

Kush Desai, MD, chief of Vascular and Interventional Radiology at Northwestern University’s Department of Radiology and a co-author of the trial, described the condition as widely underdiagnosed and undertreated. These patients suffer in silence. It’s underdiagnosed, or frankly, not diagnosed, and we have had no proven way to treat it, Desai said in the study’s accompanying materials.

The Trial: Stents as a Solution

The study, co-led by researchers at Northwestern University and Washington University School of Medicine in St. Louis, tested whether endovascular therapy—a procedure involving the placement of a metal stent to reopen blocked veins—could improve outcomes for patients with moderate to severe PTS and confirmed venous obstruction. The trial included 225 patients, who were randomly assigned to one of two groups: one receiving endovascular therapy plus standard care, and the other receiving standard care alone.

Standard care for PTS typically includes compression therapy, medications, and lifestyle changes. However, these measures often provide limited relief for patients with severe symptoms. The trial sought to determine whether restoring blood flow through stenting, combined with enhanced antithrombotic treatment, could offer more meaningful improvement.

Key Findings: Symptom Relief and Improved Quality of Life

After six months, researchers assessed symptom severity using the Venous Clinical Severity Score, a standardized tool for evaluating PTS. The results were striking: patients who received the stent procedure experienced significant reductions in pain, swelling, and disability compared to those who received standard care alone. The procedure not only alleviated physical symptoms but also improved patients’ overall quality of life, allowing many to resume daily activities that had previously been difficult or impossible.

Suresh Vedantham, MD, an interventional radiologist at Washington University School of Medicine and the national principal investigator of the trial, emphasized the transformative potential of the findings. We see a lot of patients who have moderate or severe post-thrombotic syndrome and have a tough time conducting their daily activities and maintaining a good quality of life. Many patients are unable to walk without pain or work productively, Vedantham said. The condition has been undertreated, in part because there have not been evidence-based options available. This study is the first large randomized trial to show that What we have is a treatable condition, giving patients meaningful relief from this disease.

The Broader Impact of Deep Vein Thrombosis

Deep vein thrombosis affects more than 300,000 people in the U.S. Each year, according to the study. While DVT itself can be life-threatening—particularly if a clot travels to the lungs, causing a pulmonary embolism—its long-term complications, such as PTS, often receive less attention. The new findings highlight the importance of addressing not just the acute dangers of DVT but also its chronic aftermath.

The trial’s success marks a significant step forward in the management of PTS, offering a proven intervention for a condition that has historically been difficult to treat. For patients who have struggled with chronic pain and limited mobility, the procedure could represent a turning point in their care.

What Comes Next?

While the trial’s results are promising, researchers caution that further study is needed to determine the long-term durability of the stent procedure and its effectiveness across diverse patient populations. The procedure may not be suitable for all PTS patients, particularly those without confirmed venous obstruction. Clinicians will need to carefully evaluate individual cases to determine the best course of treatment.

For now, the findings provide a much-needed evidence-based option for patients and healthcare providers. As Vedantham noted, the study opens the way to relief for a condition that has long been overlooked. With continued research and clinical adoption, stenting could become a standard part of PTS management, offering hope to thousands of patients who have suffered in silence.

Understanding the Procedure

Endovascular therapy, the procedure tested in the trial, involves inserting a thin tube (catheter) into the blocked vein, often through a small incision in the groin or leg. A balloon is then used to widen the narrowed vein, and a metal stent is placed to keep it open. The procedure is typically performed under local anesthesia and takes about one to two hours. Most patients can go home the same day or the following day.

The trial’s success underscores the potential of interventional radiology—a field that uses imaging guidance to perform minimally invasive procedures—to address complex vascular conditions. As research continues, such techniques could play an increasingly important role in improving outcomes for patients with chronic venous diseases.

A Condition No Longer Untreatable

For decades, post-thrombotic syndrome has been a frustrating and often isolating condition for patients. Many have struggled with symptoms that limit their ability to work, exercise, or even walk without discomfort. The lack of proven treatments has left both patients and clinicians searching for answers.

The publication of this trial in The New England Journal of Medicine signals a shift in the landscape of PTS care. With a proven intervention now available, patients and healthcare providers have a new tool to combat a condition that has long been considered untreatable. As awareness grows and the procedure becomes more widely adopted, the hope is that fewer patients will have to endure the chronic pain and disability associated with post-thrombotic syndrome.